Drug Profile
Research programme: PCSK9 inhibitors - Liphorus Pharmaceuticals
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Liphorus Pharmaceuticals
- Developer Clinical Research Institute of Montreal
- Class Small molecules
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypercholesterolaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Hypercholesterolaemia in Canada
- 11 Dec 2014 Early research in PCSK9 inhibitors for the treatment of Hypercholesterolaemia is ongoing in Canada
- 02 Jul 2014 European patent no. EP 2348106 B1 granted to Adaerata Limited Partnership